2023
LBA63 SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC)
Borghaei H, Johnson M, Garon E, He K, Planchard D, Reck M, Popat S, Herbst R, Leal T, Dumoulin D, de Marinis F, Reynolds C, Theelen W, Percent I, Calderon V, Flandin A, Shazer R, Yan X, Harrigan R, Peters S. LBA63 SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC). Annals Of Oncology 2023, 34: s1308. DOI: 10.1016/j.annonc.2023.10.064.Peer-Reviewed Original Research
2016
PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment
Herbst R, Baas P, Perez-Gracia J, Felip E, Kim D, Han J, Molina J, Kim J, Arvis C, Ahn M, Majem M, Fidler M, Surmont V, De Castro G, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon E. PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment. Journal Of Thoracic Oncology 2016, 11: s174-s175. DOI: 10.1016/j.jtho.2016.08.014.Peer-Reviewed Original ResearchP2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment Track: Immunotherapy
Herbst R, Baas P, Perez-Gracia J, Felip E, Kim D, Han J, Molina J, Kim J, Arvis C, Ahn M, Majem M, Fidler M, Surmont V, De Castro G, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon E. P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment Track: Immunotherapy. Journal Of Thoracic Oncology 2016, 11: s242-s243. DOI: 10.1016/j.jtho.2016.08.112.Peer-Reviewed Original ResearchLBA48 Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010
Herbst R, Baas P, Kim D, Felip E, Pérez-Gracia J, Han J, Molina J, Kim J, Arvis C, Ahn M, Majem M, Fidler M, De Castro G, Garrido M, Shentu Y, Lubiniecki G, Garon E. LBA48 Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010. Annals Of Oncology 2016, 27: vi583. DOI: 10.1093/annonc/mdw435.47.Peer-Reviewed Original Research1219P Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC
Barlesi F, Garon E, Kim D, Felip E, Han J, Kim J, Ahn M, Fidler M, Gubens M, Castro G, Surmont V, Li Q, Deitz A, Lubiniecki G, Herbst R. 1219P Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC. Annals Of Oncology 2016, 27: vi422. DOI: 10.1093/annonc/mdw383.19.Peer-Reviewed Original ResearchPembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.
Garon E, Herbst R, Kim D, Felip E, Perez-Gracia J, Han J, Molina J, Kim J, Dubos Arvis C, Ahn M, Majem M, Fidler M, Gubens M, Castro G, Garrido M, Shentu Y, Im E, Lubiniecki G, Baas P. Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010. Journal Of Clinical Oncology 2016, 34: 9024-9024. DOI: 10.1200/jco.2016.34.15_suppl.9024.Peer-Reviewed Original ResearchRelationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC.
Baas P, Garon E, Herbst R, Felip E, Perez-Gracia J, Han J, Molina J, Kim J, Dubos Arvis C, Ahn M, Majem M, Fidler M, Barlesi F, Castro G, Garrido M, Shentu Y, Lubiniecki G, Im E, Kim D. Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC. Journal Of Clinical Oncology 2016, 34: 9015-9015. DOI: 10.1200/jco.2016.34.15_suppl.9015.Peer-Reviewed Original ResearchArchival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.
Herbst R, Baas P, Perez-Gracia J, Felip E, Kim D, Han J, Molina J, Kim J, Dubos Arvis C, Ahn M, Majem M, Fidler M, Surmont V, Castro G, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon E. Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC. Journal Of Clinical Oncology 2016, 34: 3030-3030. DOI: 10.1200/jco.2016.34.15_suppl.3030.Peer-Reviewed Original Research
2014
A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer.
Herbst R, Gurpide A, Surmont V, Kim D, Waqar S, Herder J, Lee D, Carcereny E, Reguart N, Wallmark J, Ramalingam S, Langer C, Lubiniecki G, Knowles J, Zhou H, Hanson M, Baas P. A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer. Journal Of Clinical Oncology 2014, 32: tps8124-tps8124. DOI: 10.1200/jco.2014.32.15_suppl.tps8124.Peer-Reviewed Original Research
2009
9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial
Eberhardt W, Johnson B, Sun Y, Germonpré P, Saijo N, Zhou C, Wang J, Tada H, Kennedy S, Herbst R. 9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial. European Journal Of Cancer Supplements 2009, 7: 505. DOI: 10.1016/s1359-6349(09)71714-8.Peer-Reviewed Original ResearchVandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
Herbst R, Sun Y, Korfee S, Germonpré P, Saijo N, Zhou C, Wang J, Langmuir P, Kennedy S, Johnson B. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). Journal Of Clinical Oncology 2009, 27: cra8003-cra8003. DOI: 10.1200/jco.2009.27.18s.cra8003.Peer-Reviewed Original ResearchVandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
Herbst R, Sun Y, Korfee S, Germonpré P, Saijo N, Zhou C, Wang J, Langmuir P, Kennedy S, Johnson B. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). Journal Of Clinical Oncology 2009, 27: cra8003-cra8003. DOI: 10.1200/jco.2009.27.15_suppl.cra8003.Peer-Reviewed Original Research
2007
B1-06: Multicenter, randomized study of Docetaxel versus Docetaxel plus Oblimersen in patients previously treated for non-small cell lung cancer (NSCLC)
Herbst R, Ansari R, Gorbunova V, Manikhas G, Saleh M, Boyd T, Azzoli C, Robert F, Itri L, Chapman R. B1-06: Multicenter, randomized study of Docetaxel versus Docetaxel plus Oblimersen in patients previously treated for non-small cell lung cancer (NSCLC). Journal Of Thoracic Oncology 2007, 2: s335. DOI: 10.1097/01.jto.0000283144.91294.05.Peer-Reviewed Original Research
2005
O-100 ZD6474 plus docetaxel in patients with previously treatedNSCLC: Results of a randomized, placebo-controlled Phase II trial
Herbst R, Johnson B, Rowbottom J, Fidias P, Lu C, Prager D, Roubec J, Csada E, Dimery I, Heymach J. O-100 ZD6474 plus docetaxel in patients with previously treatedNSCLC: Results of a randomized, placebo-controlled Phase II trial. Lung Cancer 2005, 49: s35-s36. DOI: 10.1016/s0169-5002(05)80234-x.Peer-Reviewed Original Research
2003
Mode of action of docetaxel – a basis for combination with novel anticancer agents
Herbst RS, Khuri FR. Mode of action of docetaxel – a basis for combination with novel anticancer agents. Cancer Treatment Reviews 2003, 29: 407-415. PMID: 12972359, DOI: 10.1016/s0305-7372(03)00097-5.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsApoptosisDocetaxelDrug Resistance, NeoplasmDrug SynergismErbB ReceptorsFemaleFollow-Up StudiesHumansMaleNeoplasmsNeovascularization, PathologicPaclitaxelPharmacogeneticsSurvival AnalysisTaxoidsTreatment OutcomeConceptsPatient populationOptimal treatment strategySpecific patient populationsCertain chemotherapeutic drugsAnticancer agentsOptimal therapySpecific therapyTreatment strategiesNovel agentsClinical investigationNew anticancer agentsNovel anticancer agentsCancer growthDifferent tumorsStimulation pathwayChemotherapeutic drugsInhibitor of mitosisAntitumor activityTumorigenic mechanismsMode of actionAgent combinationsDocetaxelTherapyAgentsDifferent aberrations